Alkermes
enhanced the anti tumor efficacy of in mouse tumors tumor growth inhibition overall survival combination with growth factor pathway inhibitors days vehicle complete responses days in combination with either or not shown resulted in enhanced tumor suppression and survival relative to groups similar results observed with a mouse surrogate of which is a selective inhibitor of the angiogenesis factor alkermes internal data on file the mouse of was used in mouse tumor model | Alkermes
Company
Deck Type
Sector
Industry
Deck date
March 2021
Slide
95 of 144
Similar slides by Alkermes
See diffirences between slides (animation)
Investor Day
March 2021
in combination with growth factor pathway inhibitors enhanced cancer fighting mechanisms in mouse tumors combination with growth factor pathway inhibitors tumor gene expression in mice treated with and vehicle angiogenesis gene expression in combination with either or not shown resulted in enhanced angiogenesis blockade and activated multiple immune pathways alkermes internal data on file the mouse of was used in mouse tumor model a | Alkermes
Investor Day
March 2021
in combination with growth factor pathway inhibitors enhanced cancer fighting mechanisms in mouse tumors combination with growth factor pathway inhibitors cells in tumor cells in tumor dendritic cells in tumor dendritic cells in tumor in tumor in tumor macrophages in tumor macrophages in tumor vehicle in combination with either or not shown resulted in increased immune activation and decreased immune suppression in tumors alkermes internal data on file the mouse of was used in mouse tumor model a a | Alkermes
Related slides by other companies
Fusion Pharmaceuticals
Investor Presentation
November 2023
fusion strategy around combination therapies | Fusion Pharmaceuticals
Arbutus Biopharma
Investor Presentation
January 2024
small molecule oral inhibitor for | Arbutus Biopharma
Fusion Pharmaceuticals
Investor Presentation
August 2023
fusion strategy around combination therapies | Fusion Pharmaceuticals
Larimar Therapeutics
Investor Presentation
November 2023
extends survival in deficient mice | Larimar Therapeutics
Other recent decks by Alkermes
See all presentations (22 decks)
Investor Conference
January 2024
Results
October 2023
Investor Presentation
October 2023
Results
July 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2023 Slidebook.io